10 April 2024
10 April 2024
The Phase I/II trial will assess iadademstat in combination with immune checkpoint inhibitors in lung cancer patients.
The drug has achieved significant uptake from patients and physicians, becoming the leading glucagon-like peptide-1 receptor agonist in the type 2 diabetes and obesity markets.
Pfizer intends to submit data from MONeT to regulatory agencies in a bid to expand the vaccine’s indicated treatment population.
BrainStorm Cell Therapeutics has faced a few hurdles along the way towards the development of its lead candidate, NurOwn for ALS.
Early fosdenopterin treatment was linked to improved oral feeding abilities and motor and cognitive development in trials.
Seaport is developing oral neuropsychiatric drugs that bypass first-pass metabolism.
The two companies will address the challenges of creating scalable and compliant AI medical imaging software products.
The grant will support the preclinical development of the antibody acquired by Basilea from Spexis in January 2024.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
